Skip to main content
SpringerLink
Log in

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel®, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel® represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel® from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel® with systemic chemotherapeutic treatments such as temozolamide and O 6–benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brem H, Langer R: Polymer-based drug delivery to the brain. Sci Med July/August 3(4): 52–61, 1996

    Google Scholar 

  2. Black P: Brain tumors. Part 1 [see comments]. N Engl J Med 324(21): 1471–1476, 1991

    Google Scholar 

  3. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30(9): 907–911, 1980

    Google Scholar 

  4. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H: Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23(2): 253–266, 1989

    Google Scholar 

  5. Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI: Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80(2): 283–290, 1994

    Google Scholar 

  6. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76(4): 640–647, 1992

    Google Scholar 

  7. Fung L, Ewend M, Sills A, Sipos E, Thompson R, Watts M, Colvin O, Brem H, Saltzman W: Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58(4): 672–684, 1998

    Google Scholar 

  8. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 53(2): 329–333, 1993

    Google Scholar 

  9. Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al.: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74(3): 441–446, 1991

    Google Scholar 

  10. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group [see comments]. Lancet 345(8956): 1008–1012, 1995

    Google Scholar 

  11. Ettinger D: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come [comment]. J Clin Oncol 8(3): 374–377, 1990

    Google Scholar 

  12. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 26(2): 111–123, 1995

    Google Scholar 

  13. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41(1): 44–48; discussion 48–49, 1997

    Google Scholar 

  14. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Wamke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel® wafers) in patients with primary malignant glioma. Neuro-Oncology 5(2), 2003

  15. Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R, Markesbery W, Macdonald J, Young B: A randomized trial of surgery in the treatment of single metastases to the brain [see comments]. N Engl J Med 322(8): 494–500, 1990

    Google Scholar 

  16. Sawaya R, Ligon B, Bindal A, Bindal R, Hess K: Surgical treatment of metastatic brain tumors. J Neurooncol 27(3): 269–277, 1996

    Google Scholar 

  17. Ewend MG, Williams JA, Tabassi K, Tyler BM, Babel KM, Anderson RC, Pinn ML, Brat DJ, Brem H: Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 56(22): 5217–5223, 1996

    Google Scholar 

  18. Ewend M, Sampath P, Williams J, Tyler B, Brem H: Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43(5): 1185–1193, 1998

    Google Scholar 

  19. Sipos E, Tyler B, Piantadosi S, Burger P, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39(5): 383–389, 1997

    Google Scholar 

  20. Olivi A, Tatter S, Bruce J, Judy K, Engelhard H, Burak E, Hilt D, Grossman S, Fisher J, Piantadosi S: Toxicity and pharmacokinetics of interstitial BCNU administered via wafers: results of a Phase I study in patients with recurrent malignant glioma. 1999 Annual Meeting of the American Society of Clinical Oncology, 1999

  21. Menei P, Venier MC, Gamelin E, Sant-Andre JP, Hayek G, Jadaud E et al.: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study. Cancer 86: 324–329, 1999

    Google Scholar 

  22. Brem H, Lawson HC: The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86: 197–199, 1999

    Google Scholar 

  23. Rowinsky E, Burke P, Karp J, Tucker R, Ettinger D, Donehower R: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49(16): 4640–4647, 1989

    Google Scholar 

  24. Klecker R, Jamis-Dow C, Egorin M, Erkmen K, Parker R, Collins J: Distribution and metabolism of 3H-taxol in the rat. Proc Am Assoc Cancer Res 34: 381, 1993

    Google Scholar 

  25. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A, Brem H: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54(8): 2207–2212, 1994

    Google Scholar 

  26. Gottlieb J, Guarino A, Call J, Oliverio V, Block J: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54(6): 461–470, 1970

    Google Scholar 

  27. Moertel C, Schutt A, Reitemeier R, Hahn R: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56(1): 95–101, 1972

    Google Scholar 

  28. Muggia F, Creaven P, Hansen H, Cohen M, Selawry O: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56(4): 515–521, 1972

    Google Scholar 

  29. Weingart J, Thompson R, Tyler B, Colvin O, Brem H: Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62(5): 605–609, 1995

    Google Scholar 

  30. Hannigan E, Green S, Alberts D, O TR, Surwit E: Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50(2): 2–9, 1993

    Google Scholar 

  31. Williams P, Henner W, Roman GS, Dahlborg S, Brummett R, Tableman M, Dana B, Neuwelt E: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37(1): 17–27; discussion 27–28, 1995

    Google Scholar 

  32. VonHoff D, Schilsky R, Reichert C, Reddick R, Rozencweig M, Young R, Muggia F: Toxic effects of cis-dichlorodiammine-platinum(II) in man. Cancer Treat Rep 63(9–10): 1527–1531, 1979

    Google Scholar 

  33. Poisson M, Pereon Y, Chiras J, Delattre J: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10(2): 139–144, 1991

    Google Scholar 

  34. Olivi A, Ewend MG, Utsuki T, Tyler B, Domb AJ, Brat DJ, Brem H: Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 39(1–2): 90–96, 1996

    Google Scholar 

  35. Allen J, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55(5): 749–756, 1981

    Google Scholar 

  36. Judy KD, Olivi A, Buahin KG, Domb A, Epstein JI, Colvin OM, Brem H: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 82(3): 481–486, 1995

    Google Scholar 

  37. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79(2): 315–328, 1994

    Google Scholar 

  38. O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2): 277–285, 1997

    Google Scholar 

  39. Folkman J: Angiogenesis and angiogenesis inhibition: An overview. EXS 79: 1–8, 1997

    Google Scholar 

  40. Tamargo RJ, Leong KW, Brem H: Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol 9(2): 131–138, 1990

    Google Scholar 

  41. Weingart J, Sipos E, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82(4): 635–640, 1995

    Google Scholar 

  42. Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51(2): 672–675, 1991

    Google Scholar 

  43. Guerin C, Laterra J, Masnyk T, Golub LM, Brem H: Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188(2): 740–745, 1992

    Google Scholar 

  44. Liotta L, Steeg P, Stetler-Stevenson W: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulations. Cell 63: 327–336, 1991

    Google Scholar 

  45. Teicher B, Sotomayor E, Huang Z: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52(23): 6702–6704, 1992

    Google Scholar 

  46. Teicher B, Dupuis N, Robinson M, Emi Y, Goff D: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7(5): 237–243, 1995

    Google Scholar 

  47. Teicher B, Holden S, Ara G, Dupuis N, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 61(5): 732–737, 1995

    Google Scholar 

  48. Brem H, Gresser I, Grosfeld J, Folkman J: The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 28(10): 1253–1257, 1993

    Google Scholar 

  49. Mauceri H, Hanna N, Beckett M, Gorski D, Staba M, Stellato K, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff G, Sukhatme V, Kufe D, Weichselbaum R: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690): 287–291, 1998.

    Google Scholar 

  50. Kinsella T, Russo A, Mitchell J, Collins J, Rowland J, Wright D, Glatstein E: A Phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 11(11): 1941–1946, 1985

    Google Scholar 

  51. Williams J, Dillehay L, Tabassi K, Sipos E, Fahlman C, Brem H: Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol 32(3): 181–192, 1997

    Google Scholar 

  52. Williams J, Yuan X, Dillehay L, Shastri V, Brem H, Williams J: Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Int J Radiat Oncol Biol Phys 42(3): 631–639, 1998

    Google Scholar 

  53. Cardinale R, Dillehay L, Williams J, Tabassi K, Brem H, Lee D: Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice. Radiat Oncol Investig 6(2): 63–70, 1998

    Google Scholar 

  54. Wiranowska M, Ransohoff J, Weingart J, Phelps C, Phuphanich S, Brem H: Interferon-containing controlled-release polymers for localized cerebral immunotherapy. J Interferon Cytokine Res 18(6): 377–385, 1998

    Google Scholar 

  55. Sampath P, Hanes J, DiMeco F, Tyler BM, Brat D, Pardoll DM, Brem H: Paracrine immunotherapy with Interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Can Res 59: 2107–2114, 1999

    Google Scholar 

  56. Tamargo RJ, Sills AK Jr, Reinhard CS, Pinn ML, Long DM, Brem H: Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 74(6): 956–961, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, U.S.A

    Christopher Guerin, Alessandro Olivi, Jon D. Weingart, H. Christopher Lawson & Henry Brem

  2. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, U.S.A.

    Henry Brem

Authors
  1. Christopher Guerin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Olivi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jon D. Weingart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Christopher Lawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henry Brem
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guerin, C., Olivi, A., Weingart, J.D. et al. Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers. Invest New Drugs 22, 27–37 (2004). https://doi.org/10.1023/B:DRUG.0000006172.65135.3e

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000006172.65135.3e

Search

Navigation